Candiolo Cancer Institute - FPO, IRCCS

Candiolo 10060

0 studies enrolling now · 3 studies all time

What they study most

Advanced Cholangiocarcinoma, Cholangiocarcinoma, FGFR2 Gene Rearrangements, GIST

Studies at this site

• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Running, not enrolling
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early
• (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST — Completed